Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Neratinib
Sponsor: University Health Network, Toronto